141 related articles for article (PubMed ID: 34415581)
1. Cerebrospinal fluid neopterin as a biomarker of treatment response to Janus kinase inhibition in Aicardi-Goutières syndrome.
Han VX; Mohammad SS; Jones HF; Bandodkar S; Crow YJ; Dale RC;
Dev Med Child Neurol; 2022 Feb; 64(2):266-271. PubMed ID: 34415581
[TBL] [Abstract][Full Text] [Related]
2. Opsoclonus-myoclonus in Aicardi-Goutières syndrome.
Alburaiky S; Dale RC; Crow YJ; Jones HF; Wassmer E; Melki I; Boespflug-Tanguy O; Do Cao J; Gras D; Sharpe C
Dev Med Child Neurol; 2021 Dec; 63(12):1483-1486. PubMed ID: 34155623
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibition in the Aicardi-Goutières Syndrome.
Vanderver A; Adang L; Gavazzi F; McDonald K; Helman G; Frank DB; Jaffe N; Yum SW; Collins A; Keller SR; Lebon P; Meritet JF; Rhee J; Takanohashi A; Armangue T; Ulrick N; Sherbini O; Koh J; Peer K; Besnier C; Scher C; Boyle K; Dubbs H; Kramer-Golinkoff J; Pizzino A; Woidill S; Shults J
N Engl J Med; 2020 Sep; 383(10):986-989. PubMed ID: 32877590
[No Abstract] [Full Text] [Related]
4. Novel and emerging treatments for Aicardi-Goutières syndrome.
Tonduti D; Fazzi E; Badolato R; Orcesi S
Expert Rev Clin Immunol; 2020 Feb; 16(2):189-198. PubMed ID: 31855085
[No Abstract] [Full Text] [Related]
5. JAK Inhibition in Aicardi-Goutières Syndrome: a Monocentric Multidisciplinary Real-World Approach Study.
Frémond ML; Hully M; Fournier B; Barrois R; Lévy R; Aubart M; Castelle M; Chabalier D; Gins C; Sarda E; Al Adba B; Couderc S; D' Almeida C; Berat CM; Durrleman C; Espil C; Lambert L; Méni C; Périvier M; Pillet P; Polivka L; Schiff M; Todosi C; Uettwiller F; Lepelley A; Rice GI; Seabra L; Sanquer S; Hulin A; Pressiat C; Goldwirt L; Bondet V; Duffy D; Moshous D; Bader-Meunier B; Bodemer C; Robin-Renaldo F; Boddaert N; Blanche S; Desguerre I; Crow YJ; Neven B
J Clin Immunol; 2023 Aug; 43(6):1436-1447. PubMed ID: 37171742
[TBL] [Abstract][Full Text] [Related]
6. Elevation of proinflammatory cytokines in patients with Aicardi-Goutières syndrome.
Takanohashi A; Prust M; Wang J; Gordish-Dressman H; Bloom M; Rice GI; Schmidt JL; Crow YJ; Lebon P; Kuijpers TW; Nagaraju K; Vanderver A
Neurology; 2013 Mar; 80(11):997-1002. PubMed ID: 23408864
[TBL] [Abstract][Full Text] [Related]
7. TREX-1 related Aicardi-Goutières syndrome improved by Janus kinase inhibitor.
Ryckmans C; Donge M; Marchèse A; Mastouri M; Thomee C; Stouffs K; Lieser SL; Scalais E
Am J Med Genet A; 2024 May; 194(5):e63510. PubMed ID: 38135344
[TBL] [Abstract][Full Text] [Related]
8. Neuropathologic Impacts of JAK Inhibitor Treatment in Aicardi-Goutières Syndrome.
Jafarpour S; Suddock J; Hawes D; Santoro JD
J Clin Immunol; 2024 Feb; 44(3):68. PubMed ID: 38381212
[TBL] [Abstract][Full Text] [Related]
9. Interstitial Lung Disease and Psoriasis in a Child With Aicardi-Goutières Syndrome.
Zheng S; Lee PY; Wang J; Wang S; Huang Q; Huang Y; Liu Y; Zhou Q; Li T
Front Immunol; 2020; 11():985. PubMed ID: 32508843
[TBL] [Abstract][Full Text] [Related]
10. Ruxolitinib in Aicardi-Goutières syndrome.
Mura E; Masnada S; Antonello C; Parazzini C; Izzo G; Garau J; Sproviero D; Cereda C; Orcesi S; Veggiotti P; Zuccotti G; Dilillo D; Penagini F; Tonduti D
Metab Brain Dis; 2021 Jun; 36(5):859-863. PubMed ID: 33721182
[TBL] [Abstract][Full Text] [Related]
11. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study.
Rice GI; Forte GM; Szynkiewicz M; Chase DS; Aeby A; Abdel-Hamid MS; Ackroyd S; Allcock R; Bailey KM; Balottin U; Barnerias C; Bernard G; Bodemer C; Botella MP; Cereda C; Chandler KE; Dabydeen L; Dale RC; De Laet C; De Goede CG; Del Toro M; Effat L; Enamorado NN; Fazzi E; Gener B; Haldre M; Lin JP; Livingston JH; Lourenco CM; Marques W; Oades P; Peterson P; Rasmussen M; Roubertie A; Schmidt JL; Shalev SA; Simon R; Spiegel R; Swoboda KJ; Temtamy SA; Vassallo G; Vilain CN; Vogt J; Wermenbol V; Whitehouse WP; Soler D; Olivieri I; Orcesi S; Aglan MS; Zaki MS; Abdel-Salam GM; Vanderver A; Kisand K; Rozenberg F; Lebon P; Crow YJ
Lancet Neurol; 2013 Dec; 12(12):1159-69. PubMed ID: 24183309
[TBL] [Abstract][Full Text] [Related]
12. Different mutations in three prime repair exonuclease 1 and ribonuclease H2 genes affect clinical features in Aicardi-Goutieres syndrome.
Izzotti A; Longobardi M; Cartiglia C; Anzuini F; Arrigo P; Fazzi E; Orcesi S; Piana RL; Pulliero A
J Child Neurol; 2012 Jan; 27(1):51-60. PubMed ID: 21862834
[TBL] [Abstract][Full Text] [Related]
13. Janus Kinase Inhibitors in the Treatment of Type I Interferonopathies: A Case Series From a Single Center in China.
Li W; Wang W; Wang W; Zhong L; Gou L; Wang C; Ma J; Quan M; Jian S; Tang X; Zhang Y; Wang L; Ma M; Song H
Front Immunol; 2022; 13():825367. PubMed ID: 35418997
[TBL] [Abstract][Full Text] [Related]
14. CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation.
Hytönen J; Kortela E; Waris M; Puustinen J; Salo J; Oksi J
J Neuroinflammation; 2014 Jun; 11():103. PubMed ID: 24920219
[TBL] [Abstract][Full Text] [Related]
15. Child Neurology: Aicardi-Goutières Syndrome Presenting as Recurrent Ischemic Stroke.
Kuang SY; Li Y; Yang SL; Han X
Neurology; 2022 Aug; 99(9):393-398. PubMed ID: 35803721
[TBL] [Abstract][Full Text] [Related]
16. Cerebrospinal fluid neopterin as a biomarker of neuroinflammatory diseases.
Molero-Luis M; Casas-Alba D; Orellana G; Ormazabal A; Sierra C; Oliva C; Valls A; Velasco J; Launes C; Cuadras D; Pérez-Dueñas B; Jordan I; Cambra FJ; Ortigoza-Escobar JD; Muñoz-Almagro C; Garcia-Cazorla A; Armangué T; Artuch R
Sci Rep; 2020 Oct; 10(1):18291. PubMed ID: 33106568
[TBL] [Abstract][Full Text] [Related]
17. Cerebrospinal fluid neopterin in paediatric neurology: a marker of active central nervous system inflammation.
Dale RC; Brilot F; Fagan E; Earl J
Dev Med Child Neurol; 2009 Apr; 51(4):317-23. PubMed ID: 19191826
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neopterin, but not osteopontin, is a valuable biomarker for the treatment response in patients with HTLV-I-associated myelopathy.
Nagai M; Tsujii T; Iwaki H; Nishikawa N; Nomoto M
Intern Med; 2013; 52(19):2203-8. PubMed ID: 24088752
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of baricitinib in Japanese patients with autoinflammatory type I interferonopathies (NNS/CANDLE, SAVI, And AGS).
Kanazawa N; Ishii T; Takita Y; Nishikawa A; Nishikomori R
Pediatr Rheumatol Online J; 2023 Apr; 21(1):38. PubMed ID: 37087470
[TBL] [Abstract][Full Text] [Related]
20. Neurologic Phenotypes Associated with Mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR1, and IFIH1: Aicardi-Goutières Syndrome and Beyond.
Livingston JH; Crow YJ
Neuropediatrics; 2016 Dec; 47(6):355-360. PubMed ID: 27643693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
